<PubmedArticle>
<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
<PMID Version="1">24749763</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>06</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2036</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>39</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Alimentary pharmacology &amp; therapeutics</Title>
<ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>1349-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.12749</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anti-tumour necrosis factor-alpha agents (anti-TNF) are effective therapies for the treatment of Crohn's disease (CD), but their comparative efficacy is unknown.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To perform a network meta-analysis comparing the efficacy of anti-TNF therapies in CD.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">After screening 506 studies, reviewers extracted information on 10 studies. Traditional meta-analysis (TMA) was used to compare each anti-TNF agent to placebo. Bayesian network meta-analysis (NMA) was performed to compare the effects of anti-TNF agents to placebo. In addition, sample sizes for comparative efficacy trials were calculated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to placebo, TMA revealed that anti-TNF agents result in a higher likelihood of induction of remission and response (RR: 1.66, 95% CI: 1.17-2.36 and RR: 1.43, 95% CI: 1.17-1.73, respectively) as well as maintenance of remission and response (RR: 1.78, 95% CI: 1.51-2.09 and RR: 1.68, 95% CI: 1.46-1.93, respectively). NMA found nonsignificant trends between infliximab and adalimumab or certolizumab pegol. Among subcutaneous therapies, NMA demonstrated superiority of adalimumab to certolizumab pegol for induction of remission (RR: 2.93, 95% CrI: 1.21-7.75). Sample size calculations suggest that adequately powered head-to-head comparative efficacy trials would require greater than 3000 patients.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">All anti-TNF agents are effective for induction and maintenance of response and remission in the treatment of CD. Although adalimumab is superior to certolizumab pegol for induction of remission, there is no evidence of clinical superiority among anti-TNF agents. Head-to-head trials among the anti-TNF agents are impractical in terms of size and cost.</AbstractText>
<CopyrightInformation>Â© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stidham</LastName>
<ForeName>R W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo>
<Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>T C H</ForeName>
<Initials>TC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Higgins</LastName>
<ForeName>P D R</ForeName>
<Initials>PD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deshpande</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sussman</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singal</LastName>
<ForeName>A G</ForeName>
<Initials>AG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elmunzer</LastName>
<ForeName>B J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saini</LastName>
<ForeName>S D</ForeName>
<Initials>SD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vijan</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Waljee</LastName>
<ForeName>A K</ForeName>
<Initials>AK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>IK2 HX000775</GrantID>
<Acronym>HX</Acronym>
<Agency>HSRD VA</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM097117</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Aliment Pharmacol Ther</MedlineTA>
<NlmUniqueID>8707234</NlmUniqueID>
<ISSNLinking>0269-2813</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3WJQ0SDW1A</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B72HH48FLU</RegistryNumber>
<NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>FYS6T7F842</RegistryNumber>
<NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>UMD07X179E</RegistryNumber>
<NameOfSubstance UI="D000068582">Certolizumab Pegol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068879">Adalimumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001499">Bayes Theorem</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068582">Certolizumab Pegol</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003424">Crohn Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007140">Immunoglobulin Fab Fragments</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069285">Infliximab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011092">Polyethylene Glycols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>03</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>03</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>03</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24749763</ArticleId>
<ArticleId IdType="doi">10.1111/apt.12749</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>